Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. On March 22, 2026, Finch Therapeutics Group, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Frequently asked questions
What sector does Finch Therapeutics Group Inc (FNCH) operate in?
Finch Therapeutics Group Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Finch Therapeutics Group Inc (FNCH) current stock price?
As of the latest data, Finch Therapeutics Group Inc stock price is $7.45, with a previous close of $7.45.
What is Finch Therapeutics Group Inc (FNCH) current market capitalization?
Finch Therapeutics Group Inc market cap is approximately 11.96 million.
What is Finch Therapeutics Group Inc (FNCH) Earnings Per Share (EPS)?
The trailing EPS is -$8.80.
Does Finch Therapeutics Group Inc (FNCH) pay dividends?
No. Finch Therapeutics Group Inc does not pay a dividend.
What is Finch Therapeutics Group Inc (FNCH) beta (volatility) score?
Finch Therapeutics Group Inc has a beta of 1.174, meaning its volatility is roughly in line with the market.
